DiaSorin to Acquire Siemens' ELISA Immunodiagnostics Business

(Saluggia, Italy) has entered into an agreement to acquire Siemens Healthineers’ (Erlangen, Germany) micro-titre-based ELISA immunodiagnostic business portfolio and related tangible and intangible assets, including customer sales and distribution contracts, installed base of instruments and relevant intellectual property.

DiaSorin develops, produces and markets reagent kits for IVD worldwide, and offers a broad range of specialty tests in the immunodiagnostics market and new tests in the molecular diagnostics markets. Siemens Healthineers offers a comprehensive portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. The company’s ELISA immunodiagnostic products are marketed in hospitals, private laboratories and blood banks.

DiaSorin will acquire the ELISA immunodiagnostic business portfolio and relevant assets from Siemens Healthineers, excluding the transfer of employees or manufacturing facility and capability, on a debt-free cash-free basis for a total consideration of up to Euro 47.5 million.

Siemens Healthineers will continue to manufacture and provide its ELISA immunodiagnostic reagent kits exclusively to DiaSorin for up to three years, enabling continuous supply of its current ELISA immunodiagnostic products to customers.

The acquisition is in line with DiaSorin’s strategy to convert customers using ELISA products to its CLIA platforms and products solution, leveraging on the completeness of its CLIA menu and the features of its LIAISON platforms. Siemens Healthineers’ ELISA immunodiagnostic business portfolio will allow DiaSorin to access a significant customer base, mostly in Europe, thus providing it with the opportunity to further expand its global commercial presence to create new business opportunities for the promotion and marketing of its CLIA products.

“We are very excited to acquire the Siemens Healthineers ELISA business,” said Carlo Rosa, CEO of DiaSorin Group. “We think this deal would perfectly fit with our long-term strategy aimed at expanding our customer base leveraging on our extensive CLIA specialties menu and LIAISON Platforms.”